Past failures guide start-ups that seek to develop drugs for this silent epidemic, but will investors follow?

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Building a Better Drug for Schizophrenia, features profiles of Galenea Corp., Potomac Pharma Inc., Vanda Pharmaceuticals Inc. and Xytis Pharmaceuticals Ltd. Plus these Start-Ups Across Health Care: Aqueduct Medical Inc., CryoFluor Therapeutics LLC, 3DM Inc. and Xigen SA.

Xytis Pharmaceuticals Ltd., focused on in-licensing and developing late-stage CNS drug candidates, is taking a unique approach to treating schizophrenia by developing a drug that targets the NMDA receptor complex.